Drug
Survanta
Survanta is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_2
2
67%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(1)
Other(1)
Detailed Status
Withdrawn1
Completed1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 22 (66.7%)
N/A1 (33.3%)
Trials by Status
withdrawn133%
completed133%
unknown133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_2
Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome
NCT01203358
unknownphase_2
Efficacy and Safety of Goat Lung Surfactant for the Treatment of Respiratory Distress Syndrome in Preterm Neonates
NCT02774044
withdrawnnot_applicable
Comparison in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome
NCT01537354
Clinical Trials (3)
Showing 3 of 3 trials
NCT01203358Phase 2
Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome
NCT02774044Phase 2
Efficacy and Safety of Goat Lung Surfactant for the Treatment of Respiratory Distress Syndrome in Preterm Neonates
NCT01537354Not Applicable
Comparison in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3